Sagimet Biosciences Inc.
NASDAQ:SGMT · NASDAQ Global Market
+$0.09 today
Vol 2.63M · Avg 1.49M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:SGMT · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$43.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.35, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 -100.0% | $2.0M | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 | $0 -100.0% | $2.0M | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | 100.0% | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $39.1M +1.6% | $38.4M +94.4% | $19.8M -20.6% | $24.9M +28.8% | $19.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $17.8M +11.4% | $16.0M +23.5% | $13.0M +111.3% | $6.1M +40.1% | $4.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $56.9M +4.5% | $54.5M +66.3% | $32.7M +5.4% | $31.1M +30.9% | $23.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $0 | $0 | $0 -100.0% | $130.0K | $0 | $374.2M | $1.2B | $631.8M |
| EBITDA | -$51.0M -12.0% | -$45.6M -63.5% | -$27.9M +8.2% | -$30.4M -24.2% | -$24.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | -1393.8% | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$56.9M -4.5% | -$54.5M -77.1% | -$30.7M +1.0% | -$31.1M -30.9% | -$23.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | -1537.0% | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $5.9M -34.2% | $8.9M +210.7% | $2.9M +417.2% | $553.0K +2026.9% | $26.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $5.9M -34.2% | $8.9M +210.3% | $2.9M +415.1% | $556.0K +176.9% | -$723.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$51.0M -12.0% | -$45.6M -63.5% | -$27.9M +8.6% | -$30.5M -24.8% | -$24.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | -1393.8% | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$51.0M -12.0% | -$45.6M -63.5% | -$27.9M +8.6% | -$30.5M -24.8% | -$24.4M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | -1393.8% | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 -9.0% | -$1 +5.2% | -$2 -10.9% | -$1 -25.5% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 -9.0% | -$1 +5.2% | -$2 -10.9% | -$1 -25.5% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $32.3M +3.2% | $31.4M +72.3% | $18.2M -17.9% | $22.2M +0.0% | $22.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $32.3M +3.2% | $31.4M +72.3% | $18.2M -17.9% | $22.2M +0.0% | $22.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$503.49M
Assembly Biosciences, Inc.
NASDAQ:ASMB
$386.36M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$347.72M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$267.28M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$243.66M
Zura Bio Limited
NASDAQ:ZURA
$238.63M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$223.98M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$212.89M
Immuneering Corporation
NASDAQ:IMRX
$157.78M
Humacyte, Inc.
NASDAQ:HUMA
$157.21M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SGMT generate?
Sagimet Biosciences Inc. (SGMT) reported $0.00 of revenue in fiscal 2025.
Is SGMT profitable?
Sagimet Biosciences Inc. (SGMT) reported -$51,038,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.